TAONas-LUAD
Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lung Adenocarcinoma
Principal Investigator/s
Field / Programme
Genome Biology
Genome Biology
Summary
The EU-funded TAONas-LUAD project aims to develop a disruptive approach to lung cancer therapy, specifically to lung adenocarcinoma (LUAD) patients. The objectives are to advance on the antisense oligonucleotide (AON) therapy towards the clinic by optimizing its composition and formulation and then testing its safety and efficacy in animals. At the same time, TAONas-LUAD will develop a business plan for commercialization and incorporate a new spin off company to bring the treatment closer to patients.
The EU-funded TAONas-LUAD project aims to develop a disruptive approach to lung cancer therapy, specifically to lung adenocarcinoma (LUAD) patients. The objectives are to advance on the antisense oligonucleotide (AON) therapy towards the clinic by optimizing its composition and formulation and then testing its safety and efficacy in animals. At the same time, TAONas-LUAD will develop a business plan for commercialization and incorporate a new spin off company to bring the treatment closer to patients.
Start: 01/04/2022 End: 31/12/2025
Total Budget: 2.899.553,00 €
CRG Budget: 1.700.685,00 €
Partners
Funded by:
